Type 1 diabetes (T1D) in children involves autoimmune destruction of pancreatic ß- cells, leading to insulin deficiency. Verapamil is an L-type calcium channel blocker that has been used for decades to treat hypertension and certain cardiac conditions. Recent research has revealed its potential as a ß- cell-protective agent. Hence this study will evaluate the effect of once-daily oral verapamil on pancreatic ß- cell reserve , glycemic metrics and daily insulin requirements in children and adolescents with T1D.
Eligibility
Sex
ALL
Min age
10 Years
Max age
18 Years
Healthy volunteers
No
Inclusion Criteria:
* Children and adolescents aged 10-18 years.
* Newly diagnosed type 1 diabetes mellitus (within 6 weeks of diagnosis, defined as the day of starting insulin therapy).
* Presence of at least two positive islet autoantibody (anti glutamic acid decarboxylase antibodies, anti- tyrosine phosphataseantibodies ,anti- zinc transporter 8 protein antibodies , or anti-insulin antibodies).
* Ability to comply with study procedures.
Exclusion Criteria:
* Previous diagnosis of other endocrine disorders or autoimmune disorder (e.g. autoimmune thyroiditis).
* Current or planned use of medications that might affect glucose metabolism (e.g., corticosteroids, immunomodulators).
* Known allergy or intolerance to verapamil.
* Cardiac conduction abnormalities, heart block, or significant cardiac disease.
* Systolic or diastolic blood pressure \< 5th percentile for age and gender.
* Severe hepatic or renal impairment.
* Participation in another interventional clinical trial.
* Inability to follow the protocol for any reason as determined by the investigator.
* Elevated liver enzymes \>1.5 × upper limit of normal at screening
Primary outcome measure(s)
Peak stimulated serum C-peptide concentration after mixed meal tolerance test — 24 weeks Peak stimulated serum C-peptide concentration after mixed meal tolerance test at 6 months (24 weeks) compared to baseline.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
